Ladenburg, Germany, 27 May 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the first patient has been dosed in a Phase I clinical study evaluating HDP-102 for the treatment of non-Hodgkin lymphoma (NHL). Read more…
Pioneering cancer immunology company Asgard strengthens leadership team as it progresses its lead asset AT-108 towards clinical trials Shane brings over two decades of expertise in immunology-driven drug discovery with a specialized focus on novel modalities AT-108 is a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses Lund, Sweden, […]
225Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage Small Cell Lung Cancer or Merkel Cell Carcinoma Orphan Drug Designation follows outstanding preclinical data and FDA IND clearance Phase I/II human trials set to commence in Q1 2025 as a ‘theranostic’ targeted radionuclide treatment Berlin, Germany, 6 February 2025 – Ariceum Therapeutics (Ariceum), a […]
Additional funding from new investor Korys, joining existing syndicate members Novo Holdings and Bioqube Ventures, brings total seed financing to €21.5m Funds will be used to further develop Commit’s BiCE platform and move towards drug candidate (DC) selection Eva Van Overmeire, Senior Investment Manager at Korys, also joins Commit’s Board of Directors Mikkel Wandahl Pedersen […]
225Ac-SSO110 (satoreotide) is a first in class Actinium-labelled SSTR2 receptor antagonist Phase I/II SANTANA-225 study on track to enrol patients in Q1 2025 Berlin, Germany, 14 January 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the US Food and Drug […]
